{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:17Z","timestamp":1792839737826,"version":"4.5.0"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hepatitis C virus (HCV) infection is an independent risk factor associated with adverse outcomes in patients with end-stage renal disease (ESRD). Due to the wide variety of direct-acting antiviral regimens (DAAs) and the factor of renal insufficiency, careless selection of anti-hepatitis C treatment can lead to treatment failure and safety problems. The integrated evidence for optimized therapies for these patients is lacking. This study would conduct comparisons of different DAAs and facilitate clinical decision-making.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a systematic literature search in multiple databases (PubMed, Ovid, Embase, Cochrane Library, and Web of Science) up to 7 August 2023. Study data that contained patient characteristics, study design, treatment regimens, intention-to-treat sustained virologic response (SVR), and adverse event (AE) data per regimen were extracted into a structured electronic database and analyzed. The network meta-analysis of the estimation was performed by the Bayesian Markov Chain Monte Carlo methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our search identified 5,278 articles; removing the studies with duplicates and ineligible criteria, a total of 62 studies (comprising 4,554 patients) were included. Overall, the analyses contained more than 2,489 male individuals, at least 202 patients with cirrhosis, and no less than 2,377 patients under hemodialysis. Network meta-analyses of the DAAs found that receiving ombitasvir (OBV)\/paritaprevir (PTV)\/ritonavir (R) plus dasabuvir (DSV), glecaprevir (G)\/pibrentasvir (P), and sofosbuvir (SOF)\/ledipasvir (LDV) ranked as the top three efficacy factors for the HCV-infected ESRD patients. Stratified by genotype, the G\/P would prioritize genotype 1 and 2 patients with 98.9%\u2212100% SVR, the SOF\/DCV regimen had the greatest SVR rates (98.7%; 95% CI, 93.0%\u2212100.0%) in genotype 3, and the OBV\/PTV\/R regimen was the best choice for genotype 4, with the highest SVR of 98.1% (95% CI, 94.4%\u221299.9%). In the pan-genotypic DAAs comparison, the G\/P regimen showed the best pooled SVR of 99.4% (95% CI, 98.6%\u2212100%). DAA regimens without Ribavirin or SOF showed the lowest rates of AEs (49.9%; 95% CI, 38.4%\u221261.5%) in HCV-infected ESRD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The G\/P could be recommended as the best option for the treatment of pan-genotypic HCV-infected ESRD patients. The OBV\/PTV\/R plus DSV, SOF\/Velpatasvir (VEL), SOF\/Ledipasvir (LDV), and SOF\/DCV would be reliable alternatives for HCV treatment with comparable efficacy and safety profiles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/#searchadvanced<\/jats:ext-link>, PROSPERO: CRD42021242359.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2023.1179531","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T21:41:34Z","timestamp":1696110094000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Ruochan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/sdi.12761","article-title":"Transmission of hepatitis C virus in the dialysis setting and strategies for its prevention","volume":"32","author":"Nguyen","year":"2019","journal-title":"Semin Dial."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.5604\/01.3001.0011.7382","article-title":"Association between hepatitis C virus and chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Fabrizi","year":"2018","journal-title":"Ann Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.7326\/M19-1539","article-title":"Prevention, diagnosis, evaluation, and treatment of hepatitis C virus infection in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2018 clinical practice guideline","volume":"171","author":"Gordon","year":"2019","journal-title":"Ann Intern Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.kint.2018.06.011","article-title":"Executive summary of the 2018 KDIGO hepatitis C in CKD guideline: welcoming advances in evaluation and management","volume":"94","author":"Jadoul","year":"2018","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg."},{"key":"B8","unstructured":"WellsGA\n            SheaB\n            O'ConnellD\n            PetersonJ\n            WelchV\n            LososM\n          The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses2011"},{"key":"B9","unstructured":""},{"key":"B10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1177\/0272989X13485155","article-title":"Evidence synthesis for decision making 5: the baseline natural history model","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jvh.12553","article-title":"Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study","volume":"23","author":"Kawakami","year":"2016","journal-title":"J Viral Hepat."},{"key":"B13","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/1744-9987.12407","article-title":"Effect and safety of daclatasvir-asunaprevir combination therapy for chronic hepatitis C virus genotype 1b-infected patients on hemodialysis","volume":"20","author":"Miyazaki","year":"2016","journal-title":"Ther Apher Dial."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00535-016-1162-8","article-title":"Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C","volume":"51","author":"Suda","year":"2016","journal-title":"J Gastroenterol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00535-016-1174-4","article-title":"Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis","volume":"51","author":"Toyoda","year":"2016","journal-title":"J Gastroenterol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000454819","article-title":"Universal sustained viral response to the combination of ombitasvir\/paritaprevir\/ritonavir and dasabuvir with\/without ribavirin in patients on hemodialysis infected with hepatitis C virus genotypes 1 and 4","volume":"45","author":"Abad","year":"2017","journal-title":"Am J Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ekir.2017.04.003","article-title":"Hemodialysis patients treated for hepatitis C using a sofosbuvir-based regimen","volume":"2","author":"Agarwal","year":"2017","journal-title":"Kidney Int Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1111\/hepr.12910","article-title":"Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir in dialysis patients with genotype 1b chronic hepatitis C","volume":"47","author":"Atsukawa","year":"2017","journal-title":"Hepatol Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment [clinical trial, phase III multicenter study]","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/nep.13011","article-title":"Effectiveness of a fixed combination formula of ombitasvir\/paritaprevir\/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis","volume":"22","author":"Morisawa","year":"2017","journal-title":"Nephrology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/jvh.12664","article-title":"Therapy with ombitasvir\/paritaprevir\/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: a multicentre experience","volume":"24","author":"Munoz-Gomez","year":"2017","journal-title":"J Viral Hepat."},{"key":"B23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/jgh3.12026","article-title":"Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection","volume":"1","author":"Otsuka","year":"2017","journal-title":"Jgh Open."},{"key":"B24","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2147\/TCRM.S133983","article-title":"Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis","volume":"13","author":"Sperl","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"B25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.kint.2018.02.019","article-title":"Grazoprevir plus elbasvir in HCV genotype-1 or-4 infected patients with stage 4\/5 severe chronic kidney disease is safe and effective","volume":"94","author":"Alric","year":"2018","journal-title":"Kidney Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/apt.14799","article-title":"Effectiveness, treatment completion and safety of sofosbuvir\/ledipasvir and paritaprevir\/ritonavir\/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study [research support, Non-US Gov't]","volume":"48","author":"Butt","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/hepr.13070","article-title":"Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis","volume":"48","author":"Fujii","year":"2018","journal-title":"Hepatol Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jceh.2017.10.001","article-title":"Sofosbuvir based regimen in management of hepatitis c for patients with end stage renal disease on hemodialysis: a single center experience from India","volume":"8","author":"Gupta","year":"2018","journal-title":"J Clin Exp Hepatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s00535-017-1396-0","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection [clinical trial, phase III multicenter study]","volume":"53","author":"Kumada","year":"2018","journal-title":"J Gastroenterol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1111\/liv.13863","article-title":"Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease","volume":"38","author":"Manoj","year":"2018","journal-title":"Liver Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.antiviral.2018.10.003","article-title":"Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: a multicenter, real-world cohort study focusing on chronic kidney disease","volume":"159","author":"Ogawa","year":"2018","journal-title":"Antiviral Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/liv.13674","article-title":"High efficacy of ombitasvir\/paritaprevir\/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease","volume":"38","author":"Sanai","year":"2018","journal-title":"Liver Int."},{"key":"B33","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1159\/000488965","article-title":"Paritaprevir\/ritonavir\/ombitasvir plus dasabuvir regimen in the treatment of genotype 1 chronic hepatitis c infection in patients with severe renal impairment and end-stage renal disease: a real-life cohort","volume":"43","author":"Sperl","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00535-017-1353-y","article-title":"Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan","volume":"53","author":"Suda","year":"2018","journal-title":"J Gastroenterol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1007\/s10620-018-4979-6","article-title":"Low-dose sofosbuvir is safe and effective in treating chronic hepatitis c in patients with severe renal impairment or end-stage renal disease [observational study]","volume":"63","author":"Taneja","year":"2018","journal-title":"Dig Dis Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/jgh.14447","article-title":"Efficacy and safety of elbasvir\/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: a post hoc analysis of a multicenter study","volume":"34","author":"Atsukawa","year":"2019","journal-title":"J Gastroenterol Hepatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/apt.15218","article-title":"The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study","volume":"49","author":"Atsukawa","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4274\/vhd.galenos.2019.2019.0025","article-title":"Efficacy of direct-acting antivirals in hemodialysis patients with chronic hepatitis C: a real-life retrospective study","volume":"25","author":"Aydin","year":"2019","journal-title":"Viral Hepat J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia","year":"2019","journal-title":"J Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e5702","DOI":"10.7759\/cureus.5702","article-title":"Treatment outcomes for patients undergoing hemodialysis with chronic hepatitis C on the Sofosbuvir and daclatasvir regimen","volume":"11","author":"Butt","year":"2019","journal-title":"Cureus"},{"key":"B41","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12882-019-1631-4","article-title":"Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial","volume":"20","author":"Cheema","year":"2019","journal-title":"BMC Nephrol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s11255-019-02246-7","article-title":"Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality","volume":"51","author":"Elmowafy","year":"2019","journal-title":"Int Urol Nephrol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/nep.13222","article-title":"Daclatasvir and reduced-dose sofosbuvir: an effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate","volume":"24","author":"Goel","year":"2019","journal-title":"Nephrology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ekir.2018.10.003","article-title":"Efficacy and Safety of ombitasvir\/paritaprevir\/ritonavir in patients with hepatitis c virus genotype 1 or 4 infection and advanced kidney disease","volume":"4","author":"Lawitz","year":"2019","journal-title":"Kidney Int Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5009\/gnl18240","article-title":"Efficacy and safety of daclatasvir and asunaprevir in patients with hepatitis C virus genotype 1b infection on hemodialysis","volume":"13","author":"Lee","year":"2019","journal-title":"Gut Liver."},{"key":"B46","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.gastrohep.2018.07.015","article-title":"Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia","volume":"42","author":"Maduell","year":"2019","journal-title":"Gastroenterol Hepatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.clinre.2018.08.003","article-title":"Efficacy of ombitasvir\/paritaprevir\/ritonavir\/ribavirin in management of HCV genotype 4 and end-stage kidney disease","volume":"43","author":"Mekky","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00535-019-01556-y","article-title":"Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection [multicenter study]","volume":"54","author":"Suda","year":"2019","journal-title":"J Gastroenterol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1590\/1806-9282.65.12.1470","article-title":"Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience","volume":"65","author":"Tatar","year":"2019","journal-title":"Rev Assoc Med Bras."},{"key":"B50","doi-asserted-by":"publisher","first-page":"331","DOI":"10.5152\/tjg.2018.18269","article-title":"Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey","volume":"30","author":"Yara\u015f","year":"2019","journal-title":"Turk J Gastroenterol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e21972","DOI":"10.1097\/MD.0000000000021972","article-title":"Efficacy and safety of ombitasvir\/paritaprevir\/ ritonavir\/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease A real-life experience","volume":"99","author":"Abd-Elsalam","year":"2020","journal-title":"Medicine"},{"key":"B52","doi-asserted-by":"publisher","first-page":"104698","DOI":"10.1016\/j.antiviral.2019.104698","article-title":"Effectiveness of elbasvir\/grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population","volume":"174","author":"Choi","year":"2020","journal-title":"Antiviral Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1590\/s0004-2803.202000000-08","article-title":"Combined NS5A & NS5B nucleotide inhibitor therapy for patients with chronic hepatitis c with stage 5 chronic kidney disease on hemodialysis","volume":"57","author":"Debnath","year":"2020","journal-title":"Arq Gastroenterol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/liv.14299","article-title":"Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment","volume":"40","author":"Eletreby","year":"2020","journal-title":"Liver Int."},{"key":"B55","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jceh.2019.10.004","article-title":"Sofosbuvir\u2013velpatasvir fixed drug combination for the treatment of chronic hepatitis c infection in patients with end-stage renal disease and kidney transplantation","volume":"10","author":"Gaur","year":"2020","journal-title":"J Clin Exp Hepatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/j.transproceed.2020.02.136","article-title":"Sofosbuvir-based HCV treatment in maintenance hemodialysis patients: a single-center study","volume":"52","author":"Gohel","year":"2020","journal-title":"Transplant Proc."},{"key":"B57","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S2468-1253(19)30417-0","article-title":"Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study","volume":"5","author":"Lawitz","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e23384","DOI":"10.1097\/MD.0000000000023384","article-title":"Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C","volume":"99","author":"Li","year":"2020","journal-title":"Medicine"},{"key":"B59","doi-asserted-by":"publisher","first-page":"9180","DOI":"10.1038\/s41598-020-66182-8","article-title":"Elbasvir\/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis","volume":"10","author":"Liu","year":"2020","journal-title":"Sci. Rep"},{"key":"B60","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/jvh.13265","article-title":"Glecaprevir\/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment","volume":"27","author":"Liu","year":"2020","journal-title":"J Viral Hepat."},{"key":"B61","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/hepr.13482","article-title":"Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: a multicenter study","volume":"50","author":"Morishita","year":"2020","journal-title":"Hepatol. Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/jgh.14994","article-title":"The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment","volume":"35","author":"Poustchi","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3904\/kjim.2018.338","article-title":"Full-dose sofosbuvir plus low-dose ribavirin for hepatitis c virus genotype 2-infected patients on hemodialysis","volume":"35","author":"Seo","year":"2020","journal-title":"Korean J Intern Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1055\/s-0040-1716035","article-title":"Hepatitis C therapy with grazoprevir\/elbasvir and glecaprevir\/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R)","volume":"34","author":"Stein","year":"2020","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3350\/cmh.2020.0058","article-title":"Use of glecaprevir\/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment","volume":"26","author":"Yap","year":"2020","journal-title":"Clin Mol Hepatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e0237582","DOI":"10.1371\/journal.pone.0237582","article-title":"Glecaprevir-pibrentasvir for chronic hepatitis C: comparing treatment effect in patients with and without end-stage renal disease in a real-world setting","volume":"15","author":"Yen","year":"2020","journal-title":"PLoS ONE"},{"key":"B67","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jmii.2020.05.004","article-title":"Elbasvir\/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: a real world multicenter observatory study in Taiwan","volume":"54","author":"Cheng","year":"2021","journal-title":"J Microbiol Immunol Infect."},{"key":"B68","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/gutjnl-2020-323569","article-title":"Sofosbuvir\/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment","volume":"71","author":"Liu","year":"2021","journal-title":"Gut"},{"key":"B69","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/liv.14685","article-title":"Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis","volume":"41","author":"Taneja","year":"2021","journal-title":"Liver Int."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/liv.14320","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection","volume":"40","author":"Lawitz","year":"2020","journal-title":"Liver Int."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.31450\/ukrjnd.2(66).2020.01","article-title":"The outcome of daclatasvir and low dose sofosbuvir therapy in end-stage renal disease patients with hepatitis C virus infection","author":"Mostafi","year":"2020","journal-title":"Ukr J Nephrol Dial."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1136\/gutjnl-2020-323277","article-title":"Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C)","volume":"70","author":"Yu","year":"2021","journal-title":"Gut."},{"key":"B73","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cgh.2016.10.034","article-title":"Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection: a systematic review and network meta-analysis","volume":"15","author":"Berden","year":"2017","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"Electronic Address EEE, Clinical Practice Guidelines Panel C, representative EGB, Panel Members. EASL recommendations on treatment of hepatitis C: final update of the series(\u22c6)","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American association for the study of liver diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C Virus Infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1179531\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T21:41:37Z","timestamp":1696110097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1179531\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":75,"alternative-id":["10.3389\/fpubh.2023.1179531"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1179531","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,29]]},"article-number":"1179531"}}